Turn on gene to treat disease by RNAa

FOLLOW OUR PROGRESS

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

Thursday, January 27, 2022

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

[01/27/2022, Nantong] Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital. This capital will be used to advance serval programs from preclinical to clinical phase, as well as scale-up its oligonucleotide manufacturing capabilities.

“We feel fortunate to have attracted the support of well-respected investors from within and outside of China.” said Dr. Long-Cheng Li, Chief Executive Officer of Ractigen Therapeutics. “Our mission at Ractigen Therapeutics is to offer a practical solution to combat disease caused by insufficient protein levels using saRNA to restore target gene expression. These new funds will allow us to continue development of our lead saRNA drug candidates into the clinic.”

“RNAa has broad application for the treatment of many genetic disorders. Ractigen Therapeutics has built a diverse pipeline containing programs covering monogenic diseases, oncology, and liver-related indications.” said a Director of SDIC-VC. “We are very optimistic about the potential of Ractigen Therapeutics and expect major breakthroughs in the near future as they advance their drug candidates into patients.”